Guardant Health (NASDAQ:GH) announced its earnings results on Thursday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.25, Briefing.com reports. Guardant Health had a negative return on equity of 22.93% and a negative net margin of 60.08%. The company had revenue of $60.85 million for the quarter, compared to analyst estimates of $45.40 million. During the same period in the prior year, the company posted ($1.94) EPS. Guardant Health’s quarterly revenue was up 180.4% on a year-over-year basis.
Shares of GH traded up $7.69 during trading on Friday, reaching $71.89. The company’s stock had a trading volume of 3,794,600 shares, compared to its average volume of 1,093,573. Guardant Health has a twelve month low of $31.06 and a twelve month high of $112.21. The company has a market cap of $6.32 billion and a price-to-earnings ratio of -25.68. The company has a fifty day moving average of $66.52 and a two-hundred day moving average of $80.32.
In related news, Chairman Amirali Talasaz sold 100,000 shares of the firm’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $100.17, for a total transaction of $10,017,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Richard B. Lanman sold 5,764 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $67.99, for a total value of $391,894.36. In the last three months, insiders sold 5,883,465 shares of company stock valued at $474,143,453. Company insiders own 13.00% of the company’s stock.
A number of equities analysts have issued reports on GH shares. ValuEngine raised Guardant Health from a “hold” rating to a “buy” rating in a research report on Friday, November 1st. Cowen set a $110.00 target price on Guardant Health and gave the company a “buy” rating in a research report on Wednesday, August 7th. Zacks Investment Research lowered Guardant Health from a “buy” rating to a “hold” rating in a research report on Thursday. JPMorgan Chase & Co. upped their target price on Guardant Health from $90.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $125.00 target price on shares of Guardant Health in a research report on Friday. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $104.40.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Story: Support Level
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.